Dimethyltryptamine molecule:

Image from PubChem

DMT Clinical Trials


A Double-blind, Randomised, Placebo-controlled Study of Intravenous Doses of SPL026 (DMT Fumarate), a Serotonergic Psychedelic, in Healthy Subjects (Part A) and Patients With Major Depressive Disorder (Part B)


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04673383

Organisation Name: Small Pharma Ltd

Overal Status: Recruiting

Start Date: February 4, 2021

Last Update: March 19, 2021

Lead Sponsor: Small Pharma Ltd

Brief Summary: SPL026 (N,N-dimethyltryptamine [DMT] fumarate) is a psychedelic tryptamine being developed as a therapy for patients with major depressive disorder (MDD).

Conditions:
  • Major Depressive Disorder


Total execution time in seconds: 0.5066499710083